H.U. Group Holdings (TSE:4544) Wins Fresh Diagnostic Approvals, Is It Fully Priced?
H.U. Group Holdings (TSE:4544) drew fresh attention after Brazilian regulator ANVISA cleared Fujirebio’s Lumipulse G NfL Blood and pTau 217 Plasma assays, along with new Class II licenses from Health Canada.
These approvals arrive after a 90-day share price return of 10.97%, which builds on a 5.23% year-to-date gain for H.U. Group Holdings. The 3-year total shareholder return of 57.78% points to momentum that predates this latest regulatory milestone.
Scan beyond H.U. Group Holdings and see how other healthcare diagnostics players stack up on quality and valuation using our curated list of solid balance sheet and fundamentals (22 results)
Bulls see H.U. Group Holdings as a discounted diagnostics platform gaining fresh regulatory traction, while bears point to the recent share price run. Which side does the valuation actually favor?
Price-to-Earnings of 20.7x: Is it justified?
On simple numbers, H.U. Group Holdings trades on a P/E of 20.7x, which sits above both its own fair ratio estimate and the wider healthcare pack.
The P/E multiple compares the current share price to earnings per share and gives a quick read on how much investors are willing to pay for each unit of profit. For a diagnostics and healthcare services group like H.U. Group Holdings, that figure often reflects how durable the earnings base looks and how much confidence there is in future profit growth.
Recent profit trends are mixed. Earnings growth over the past year is very large and far stronger than both the broader Healthcare industry and the company’s own 5 year record, and net profit margins have moved from 0.6% to 3.9%. At the same time, the business has a history of earnings decline over 5 years, relies on higher risk funding, and recent results include a sizeable ¥5.8b one off gain, which can make current profits look healthier than underlying operations alone would suggest.
Relative to peers, the premium is clear. The current P/E of 20.7x is well above the JP Healthcare industry average of 14.1x and also higher than the peer group average of 14.6x. It also sits above the estimated fair P/E of 19.1x. This points to a level the market could move toward if enthusiasm for the stock cools or earnings growth settles closer to forecasts.
Explore the SWS fair ratio for H.U. Group Holdings.
Result: Price-to-Earnings of 20.7x (OVERVALUED)
Still, a premium P/E for H.U. Group Holdings could unwind quickly if one-off gains fade or if regulatory momentum around key assays slows.
Find out about the key risks to this H.U. Group Holdings narrative.
Another View: DCF points the other way
The P/E screen paints H.U. Group Holdings as expensive, yet the SWS DCF model points in the opposite direction. At ¥3,600, the stock is trading about 40.4% below an estimated future cash flow value of ¥6,038.24. Which signal should carry more weight for you?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out H.U. Group Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 19 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
There are mixed signals on H.U. Group Holdings so far. If you want to move quickly and form your own view, start with the 3 key rewards and 2 important warning signs.
Looking for more H.U. Group Holdings sized opportunities?
Do not stop your research with H.U. Group Holdings. Cast a wider net and you might spot opportunities other investors overlook before they catch on.
- Target resilient ideas that aim to protect your capital first by scanning a curated set of 21 resilient stocks with low risk scores.
- Hunt for quality at a discount by reviewing a focused group of 19 high quality undervalued stocks that combine fundamentals with appealing valuations.
- Strengthen your income game by checking out companies in the 14 dividend fortresses that aim to deliver yields of 5% or higher.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com